First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

Date publication

juin 2015

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ZANETTA Sylvie

Tous les auteurs :
Ravaud A, Oudard S, De Fromont M, Chevreau C, Gravis G, Zanetta S, Theodore C, Jimenez M, Sevin E, Laguerre B, Rolland F, Ouali M, Culine S, Escudier B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25802238

Résumé

Papillary renal cell carcinoma (PRCC), type 1 and type 2, represents 10%-15% of renal cell carcinomas (RCC). There is no standard first-line treatment of metastatic PRCC (mPRCC). Anti-angiogenics have shown activity in retrospective studies but no prospective studies in pure papillary histology have been reported, but one with foretinib.

Mots clés

anti-angiogenic, papillary renal cell carcinoma, renal cell carcinoma, sunitinib, type 1 papillary renal cell carcinoma, type 2 papillary renal cell carcinoma

Référence

Ann. Oncol.. 2015 Jun;26(6):1123-8